Section Edited by Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
Chemical priming of natural killer cells with branched polyethylenimine for cancer immunotherapySeung Hee Choi, Hye Jin Kim, Joo Dong Park, Eun-Su Ko, Minwook Lee, Dae-Keum Lee, Jin-Ho Choi, Hye Jung Jang, Isaac Kim, Hae-Yun Jung, Keun-Hong Park, Kyung-Soon Park
26 August 2022
Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cellsCelia Martín-Otal, Aritz Lasarte-Cia, Diego Serrano, Noelia Casares, Enrique Conde, Flor Navarro, Inés Sánchez-Moreno, Marta Gorraiz, Patricia Sarrión, Alfonso Calvo, Carlos E De Andrea, José Echeveste, Amaia Vilas, Juan Roberto Rodriguez-Madoz, Jesús San MiguelSee the full list of authors
2 August 2022
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumorsSophia Stock, Mohamed-Reda Benmebarek, Anna-Kristina Kluever, Diana Darowski, Christian Jost, Kay-Gunnar Stubenrauch, Joerg Benz, Anne Freimoser-Grundschober, Ekkehard Moessner, Pablo Umana, Marion Subklewe, Stefan Endres, Christian Klein, Sebastian Kobold
28 July 2022
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signalingSamantha M Fix, Marie-Andrée Forget, Donastas Sakellariou-Thompson, Yunfei Wang, Tamara M Griffiths, Minjung Lee, Cara L Haymaker, Ana Lucía Dominguez, Rafet Basar, Christopher Reyes, Sanjay Kumar, Larissa A Meyer, Patrick Hwu, Chantale Bernatchez, Amir A Jazaeri
26 July 2022
Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapyNada S Aboelella, Caitlin Brandle, Ogacheko Okoko, Md Yeashin Gazi, Zhi-Chun Ding, Hongyan Xu, Gregory Gorman, Roni Bollag, Marco L Davila, Locke J Bryan, David H Munn, Gary A Piazza, Gang Zhou
26 July 2022
Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapyPhilip C Simister, Ellen C Border, João F Vieira, Nicholas J Pumphrey
17 July 2022
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemiaRim Trad, Walid Warda, Vincent Alcazer, Mathieu Neto da Rocha, Ana Berceanu, Clémentine Nicod, Rafik Haderbache, Xavier Roussel, Yohan Desbrosses, Etienne Daguindau, Florain Renosi, Christophe Roumier, Lucie Bouquet, Sabeha Biichle, Melanie GuiotSee the full list of authors
8 July 2022
Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancersQingyang Li, Wei Hu, Baoyi Liao, Chanchan Song, Liangping Li
7 July 2022
Non-synergy of PD-1 blockade with T-cell therapy in solid tumorsJohn S Davies, Farrah Karimipour, Ling Zhang, Nisha Nagarsheth, Scott Norberg, Carylinda Serna, Julius Strauss, Shinheng Chiou, James L Gulley, Christian S Hinrichs
6 July 2022
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndromeMikiya Ishihara, Shigehisa Kitano, Shinichi Kageyama, Yoshihiro Miyahara, Noboru Yamamoto, Hidefumi Kato, Hideyuki Mishima, Hiroyoshi Hattori, Takeru Funakoshi, Takashi Kojima, Tetsuro Sasada, Eiichi Sato, Sachiko Okamoto, Daisuke Tomura, Ikuei NukayaSee the full list of authors
29 June 2022